Evidence map›Paper›PMID 32730809›Full record

ArticleCell2020

An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells.

Ekaterina V Vinogradova, Xiaoyu Zhang, David Remillard, Daniel C Lazar, Radu M Suciu, Yujia Wang, Giulia Bianco, Yu Yamashita, Vincent M Crowley, Michael A Schafroth and 18 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 222 papers.

0numbers the graph read from it
0cells of the map it votes in
222citing papers in PubMed
20.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

222 citing papers in PubMed, 358 citations in OpenAlex.

  1. Beyond the obvious pocket.Nature chemical biology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The Development of UM-232, a Covalent STING Antagonist.ACS medicinal chemistry letters · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

162 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 5 institutions in 2 countries.

Ekaterina V VinogradovaDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: vinograd@scripps.edu.
Xiaoyu ZhangDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
David RemillardDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Daniel C LazarDepartment of Immunology and Infectious Disease, The Scripps Research Institute, La Jolla, CA 92037, USA.
Radu M SuciuDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Yujia WangDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Giulia BiancoDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Yu YamashitaDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA; Medicinal Chemistry Research Laboratories, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., 463-10 Kawauchi-cho, Tokushima 771-0192, Japan.
Vincent M CrowleyDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Michael A SchafrothDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Minoru YokoyamaDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
David B KonradDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Kenneth M LumDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Gabriel M SimonVividion Therapeutics, 5820 Nancy Ridge Drive, San Diego, CA 92121, USA.
Esther K KemperDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Michael R LazearDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Sifei YinDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Megan M BlewettDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Melissa M DixDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Nhan NguyenDepartment of Immunology and Infectious Disease, The Scripps Research Institute, La Jolla, CA 92037, USA.
Maxim N ShokhirevRazavi Newman Integrative Genomics and Bioinformatics Core, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
Emily N ChinDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Luke L LairsonDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Bruno MelilloDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA; Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA 02138, USA.
Stuart L SchreiberChemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA 02138, USA; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Stefano ForliDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
John R TeijaroDepartment of Immunology and Infectious Disease, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: teijaro@scripps.edu.
Benjamin F CravattDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: cravatt@scripps.edu.
Scripps Research Institute · USBroad Institute · USOtsuka (Japan) · JPSalk Institute for Biological Studies · USVividion Therapeutics (United States) · US

Funding

Viral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Alan Saghatelian · 1985 to 2026
$82.8M
Scripps Translational Science InstituteUL1TR001114 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI TOPOL, ERIC JEFFREY · 2013 to 2017
$24.0M
AutoDock Suite: Next Generation Environment for Drug DesignR01GM069832 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI FORLI, STEFANO · 2004 to 2025
$10.9M
Chemical Proteomic Platforms for Radically Expanding Cancer DruggabilityR35CA231991 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI BENJAMIN F CRAVATT · 2018 to 2026
$9.5M
The Discovery of Human Peptide Encoding GenesR01GM102491 · NIGMS · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI O'SHEA, CLODAGH, SAGHATELIAN, ALAN · 2012 to 2025
$5.5M
Studies of Materials with Physiological PropertiesR35GM127045 · NIGMS · BROAD INSTITUTE, INC. · PI SCHREIBER, STUART L · 2018 to 2022
$3.2M
Application of (chemo)proteomic methods to map cancer biochemical pathwaysR50CA211526 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI SIMON, MELISSA DIX · 2016 to 2020
$843k
The Development of Organelle Specific Hsp90 Isoform-Selective InhibitorsK00CA212467 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI CROWLEY, VINCENT · 2018 to 2021
$316k
Discovery of small molecule-mediated protein degradation pathways in human cancerK99CA248715 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI ZHANG, XIAOYU · 2020 to 2021
$247k
The Development of Organelle Specific Hsp90 Isoform-Selective InhibitorsF99CA212467 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI CROWLEY, VINCENT · 2016 to 2017
$63k
NCATS NIH HHS UL1 TR001114NCI NIH HHS F99 CA212467NCI NIH HHS K00 CA212467NCI NIH HHS K99 CA248715NCI NIH HHS P30 CA014195NCI NIH HHS R35 CA231991NCI NIH HHS R50 CA211526NIGMS NIH HHS R01 GM069832NIGMS NIH HHS R01 GM102491NIGMS NIH HHS R35 GM127045
6 · The paper itself

Abstract

Electrophilic compounds originating from nature or chemical synthesis have profound effects on immune cells. These compounds are thought to act by cysteine modification to alter the functions of immune-relevant proteins; however, our understanding of electrophile-sensitive cysteines in the human immune proteome remains limited. Here, we present a global map of cysteines in primary human T cells that are susceptible to covalent modification by electrophilic small molecules. More than 3,000 covalently liganded cysteines were found on functionally and structurally diverse proteins, including many that play fundamental roles in immunology. We further show that electrophilic compounds can impair T cell activation by distinct mechanisms involving the direct functional perturbation and/or degradation of proteins. Our findings reveal a rich content of ligandable cysteines in human T cells and point to electrophilic small molecules as a fertile source for chemical probes and ultimately therapeutics that modulate immunological processes and their associated disorders.

Indexed as

LigandsAcetamidesAcrylamidesCells, CulturedCysteineHumansInhibitor of Apoptosis ProteinsLymphocyte ActivationProtein-Tyrosine KinasesProteolysisProteomeStereoisomerismT-LymphocytesUbiquitin-Protein LigasesAcetamidesAcrylamidesBIRC2 protein, humanchloroacetamideCysteineemt protein-tyrosine kinaseInhibitor of Apoptosis ProteinsLigandsProtein-Tyrosine KinasesProteomeUbiquitin-Protein Ligasesactivity-based protein profilingBIRC3chemical proteomicscovalentcysteineelectrophileshumanITKprotein degradationT cells

Identifiers

PMID32730809
PMCPMC7775622
OpenAlexW3045530700

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.